Peter Hellemans

1.9k citations

57 papers · 1.4k indexed · h-index 20

Impact in

Genetics top 2%
- Chronic Lymphocytic Leukemia Research
Hematology top 5%
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments

Papers in ⓘ

Hematology 17
- Multiple Myeloma Research and Treatments 14
Genetics 14
- Chronic Lymphocytic Leukemia Research 14

Co-authors: A.T. van Oosterom (3 shared papers)P. Buytaert (2 shared papers)Johan W. Smit (7 shared papers)Joost Weyler (1 shared paper)Jan Gerris (4 shared papers)Eric Van Marck (1 shared paper)Jan de Jong (11 shared papers)Ronald de Vries (5 shared papers)
Journals: Journal of Clinical Oncology (13 papers)Blood (10 papers)Cancer Chemotherapy and Pharmacology (4 papers)Clinical Cancer Research (3 papers)Cancer Research (2 papers)
Partner nations: Belgium United States Spain

In The Last Decade

Peter Hellemans

56 papers receiving 1.3k citations

Peers

Countries citing papers authored by Peter Hellemans

Since Specialization

Citations

This map shows the geographic impact of Peter Hellemans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hellemans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hellemans more than expected).

Fields of papers citing papers by Peter Hellemans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Hellemans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hellemans. The network helps show where Peter Hellemans may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Hellemans, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Hellemans Line = papers co-authored together Peter Hellemans links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 57 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study The Lancet Oncology ·Anas Younes, Catherine Thiéblemont, Franck Morschhauser, Ian W. Flinn, Jonathan W. Friedberg, Sandy Amorim, Bénédicte Hivert, Jason R. Westin, Jessica Vermeulen, Nibedita Bandyopadhyay, Ronald de Vries, Sriram Balasubramanian, Peter Hellemans, Johan W. Smit, Nele Fourneau, Yasuhiro Oki	2014	186
2	Prognostic value of bcl-2 expression in invasive breast cancer British Journal of Cancer ·Peter Hellemans, PA van Dam, Joost Weyler, A.T. van Oosterom, P. Buytaert, Eric Van Marck	1995	166
3	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, Steve Mcclue, Johan W. Smit, Ann Forslund, Charles E. Phelps, A. John Camm, T.R. Jeffry Evans, Johann S. de Bono, Udai Banerji	2013	97
4	Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants Pharmacology Research & Perspectives ·Jan de Jong, Donna Skee, Joe Murphy, Juthamas Sukbuntherng, Peter Hellemans, Johan W. Smit, Ronald de Vries, Juhui James Jiao, Jan Snoeys, Erik Mannaert	2015	81
5	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma Blood ·Saad Z. Usmani, Hareth Nahi, María‐Victoria Mateos, Niels W.C.J. van de Donk, Ajai Chari, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Kevin Liu, Jesús F. San Miguel	2019	80
6	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation Clinical Cancer Research ·Martijn P. Lolkema, Hilde Bohets, Hendrik‐Tobias Arkenau, Ann Lampo, Erio Barale-Thomas, Maja J.A. de Jonge, Leni van Doorn, Peter Hellemans, Johann S. de Bono, Ferry A.L.M. Eskens	2015	68
7	Fetal fibronectin detection for prediction of preterm birth in low risk women BJOG An International Journal of Obstetrics & Gynaecology ·Peter Hellemans, Jan Gerris, Petra Verdonk	1995	62
8	The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia Cancer Chemotherapy and Pharmacology ·Jan de Jong, Juthamas Sukbuntherng, Donna Skee, Joe Murphy, Susan O’Brien, John C. Byrd, Danelle F. James, Peter Hellemans, David Loury, Juhui J. Jiao, Vijay S. Chauhan, Erik Mannaert	2015	60
9	Stable isotope‐labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults British Journal of Clinical Pharmacology ·Ronald de Vries, Johan W. Smit, Peter Hellemans, James Jiao, Joseph Murphy, Donna Skee, Jan Snoeys, Juthamas Sukbuntherng, Maarten Vliegen, Loeckie De Zwart, Erik Mannaert, Jan de Jong	2015	58
10	Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB – IVA mycosis fungoides/Sézary syndrome British Journal of Dermatology ·Fiona Child, Pablo L. Ortiz‐Romero, Rute Alvarez, M. Bagot, Rudolf Stadler, Michael Weichenthal, Rita Valério Alves, Pietro Quaglino, M. Beylot‐Barry, Richard Cowan, Larisa J. Geskin, A. Pérez‐Ferriols, Peter Hellemans, Yusri Elsayed, Charles E. Phelps, Ann‐Sofie Forslund, Makio Kamida, Pier Luigi Zinzani	2016	47
11	Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer Clinical Pharmacokinetics ·Ignacio Durán, Joan Carles, Iurie Bulat, Peter Hellemans, Anna Mitselos, Peter Ward, James Jiao, Danielle Armas, Caly Chien	2020	42
12	A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies Leukemia & lymphoma ·Jan de Jong, Peter Hellemans, Severijn De Wilde, Daniel Patricia, Tara Masterson, Georgii Manikhas, Alexander Myasnikov, Dzhelil Osmanov, Raúl Córdoba, Carlos Panizo, Loeckie De Zwart, Jan Snoeys, Vijay S. Chauhan, James Jiao, Juthamas Sukbuntherng, Danièle Ouellet	2018	33
13	Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. Journal of Clinical Pathology ·Peter Hellemans, Peter A. van Dam, Michael Geyskens, A.T. van Oosterom, P. Buytaert, E. Van Marck	1995	29
14	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO) Haematologica ·Jesús F. San Miguel, Saad Z. Usmani, María‐Victoria Mateos, Niels W.C.J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Kevin Liu, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Andrew Farnsworth, Hareth Nahi, Ajai Chari	2020	25
15	Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility Fertility and Sterility ·Jan Gerris, Frank Comhaire, Peter Hellemans, Koen Peeters, F. Schoonjans	1991	24
16	Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma Leukemia & lymphoma ·Philippe Moreau, Thierry Façon, Cyrille Touzeau, Lotfi Benboubker, Martine Delain, Julie Badamo-Dotzis, Charles E. Phelps, Christopher Doty, Hans Smit, Nele Fourneau, Ann Forslund, Peter Hellemans, Xavier Leleu	2016	24
17	Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study Blood ·Ajai Chari, Hareth Nahi, María‐Victoria Mateos, Henk M. Lokhorst, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Kevin Liu, Jesús F. San Miguel, Saad Z. Usmani	2017	24
18	Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study Cancer Chemotherapy and Pharmacology ·Jan de Jong, Peter Hellemans, James Jiao, Yuhan Huang, Sofie Mesens, Juthamas Sukbuntherng, Danièle Ouellet	2017	22
19	An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer Cancer Chemotherapy and Pharmacology ·Bodine P.S. Belderbos, Ronald de Wit, Caly Chien, Anna Mitselos, Peter Hellemans, James Jiao, Margaret K. Yu, Gerhardt Attard, Iurie Bulat, W. Jeffrey Edenfield, Fred Saad	2018	22
20	Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO) Blood ·Saad Z. Usmani, Hareth Nahi, María‐Victoria Mateos, Henk M. Lokhorst, Ajai Chari, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Tahamtan Ahmadi, Kevin Liu, Jesús F. San Miguel	2016	21

About Peter Hellemans

Peter Hellemans is a scholar working on Hematology, Genetics, Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 57 papers that have together received 1.4k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (14 papers), Multiple Myeloma Research and Treatments (14 papers), Monoclonal and Polyclonal Antibodies Research (11 papers), Lymphoma Diagnosis and Treatment (10 papers), Protein Degradation and Inhibitors (9 papers), Peptidase Inhibition and Analysis (9 papers), HER2/EGFR in Cancer Research (8 papers) and Histone Deacetylase Inhibitors Research (8 papers). The work is most often cited by research in Genetics (381 citations), Hematology (272 citations), Pathology and Forensic Medicine (363 citations), Oncology (533 citations) and Pharmacology (80 citations). Peter Hellemans has collaborated with scholars based in Belgium, United States and Spain. Frequent co-authors include A.T. van Oosterom, P. Buytaert, Johan W. Smit, Joost Weyler, Jan Gerris, Eric Van Marck, Jan de Jong, Ronald de Vries, Juthamas Sukbuntherng and Petra Verdonk. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer Chemotherapy and Pharmacology, Clinical Cancer Research and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact